Previous 10 | Next 10 |
2023-06-14 06:28:00 ET Summary We’ve seen signs of improvement that are positive for the Chinese internet services sector, but that space also continues to be a place of extreme competitive aggression. As a result of the creation of economic zones, increased availability of...
- New follow-up results from Phase 3 SEQUOIA trial and post hoc safety analyses for BRUKINSA ® (zanubrutinib) reinforce potential across various B-cell malignancies - Early results for BTK-targeted CDAC (BGB-16673) and BCL-2 inhibitor (BGB-11417) in various B-cell malignanc...
2023-06-01 05:16:01 ET Summary Baker Brothers' 13F portfolio value increased from $16.65B to $18.38B, with the largest five stakes in Seagen, Incyte, BeiGene, ACADIA Pharma, and Madrigal Pharma. The firm disposed of its stakes in Ascendis Pharma A/S and Horizon Therapeutics, while...
BeiGene’s BTKi is approved in more than 65 markets globally BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, announced today that BRUKINSA (zanubrutinib), a Bruton's tyrosine kinase inhibitor (BTKi), has been approved by Health Canada fo...
Health Canada Approves(PR) BRUKINSA® (zanubrutinib) for the Treatment of Chronic Lymphocytic Leukemia (CLL), the Most Common Leukemia in Adults Canada NewsWire Two global Phase 3 trials in adults with CLL demonstrated superior efficacy for BRUKINSA in first line a...
2023-05-27 12:00:00 ET The anxiety over a potential wave of COVID cases impacting economic activity may be overwrought, according to fresh analysis from Cowen. The firm said there are a number of reasons to be optimistic that sweeping reports of a large number of Omicron variant XBB cas...
Highlights from early- and late-stage pipeline include -- combination data for cornerstone therapies BRUKINSA and tislelizumab -- early results for OX40 agonist BGB-A445 and BCL-2 inhibitor BGB-11417 BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnolog...
The Max Foundation (Max), a global nonprofit organization dedicated to accelerating health equity by delivering medication, technology, and supportive services to patients worldwide, BeiGene, a global biotechnology company, and the BeiGene Foundation, a nonprofit charitable foundation, today anno...
2023-05-11 07:23:00 ET Summary BeiGene’s revenue in the first quarter grew 56% while global sales of its core cancer drug doubled. The company’s sales costs are rising even faster than its R&D spending. As well as spending heavily on R&D and sales, BeiGen...
BRUKINSA is approved for first-line treatment for CLL/SLL and WM in China and has multiple approved indications in more than 65 markets worldwide BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced the China National Medical Products Adminis...
News, Short Squeeze, Breakout and More Instantly...
$800 million investment in New Jersey supports global growth and expansion with technologically advanced manufacturing capacity and clinical development capabilities for novel cancer medicines BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today ann...
2024-07-20 02:44:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
BeiGene , Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced the appointment of Aaron Rosenberg as Chief Financial Officer, effective July 22. Mr. Rosenberg will succeed Julia Wang, who is departing to pursue external opportunities and will stay with the C...